Back to news list

Share

Breast Cancer Group,Head and Neck Cancer Group,Lung Cancer Group,News

EORTC’s presence at ESMO 2023

17 Oct 2023

New findings and upcoming EORTC trials in lung, head and neck, breast and rare cancers will be presented at ESMO 2023 in Madrid, highlighting EORTC’s commitment to innovative non-commercial cancer research. Seven abstracts have been accepted, with one of them being an oral presentation. Additionally, EORTC’s Scientific Director, Jan Bogaerts, will delve into the realm of pragmatic trials during a special session on Sunday, 22 October 2023. For a comprehensive overview of EORTC’s activities at ESMO, please refer to the table below.

EORTC presentations:

Presentation title Presentation details
Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI): Two years update
Madeline Pe, Belgium		 Friday, 20 October 2023 at 2:00 PM
Room: Ávila Auditorium – NCC
Pragmatic Trials
Jan Bogaerts, Belgium		 Sunday, 22 October 2023 at 10:15 AM
Room: León Auditorium – Hall 7

EORTC abstracts accepted at ESMO:

Cancer type Abstract Title Presentation Details & Abstract Number
Breast Cancer EORTC BCG 1984 – NOBLE – Neoadjuvant Olaparib and Durvalumab for patients with BRCA-associated TripLE Negative Breast Cancer.
Emanuel Buhrer, Belgium		 Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 351TiP
Breast Cancer Deep Learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study.
Christian Esposito, France		 Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 2274P
Lung Cancer IMMUcan consortium: focus on the first non-small cell lung cancer (NSCLC) cohort.
Marie Morfouace, Germany		 Saturday, 21 October 2023
Type: Poster Display
Abstract Number: 2266P
Rare Cancers Molecular profiling of 991 prospectively recruited patients with rare cancers in EUROPE: First results of ARCAGEN – a EORTC-SPECTA and EURACAN study.
Marie Morfouace, Germany		 Sunday, 22 October 2023 at 08:30 AM
Type: Mini Oral session
Room: Santander Auditorium – Hall 9
Abstract Number: 132MO
Head and Neck Carcinoma A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Rachel Galot, Belgium		 Sunday, 22 October 2023
Type: Poster Display
Abstract Number: 935P
Lung Cancer The 1825-EORTC, ALKALINE: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor.
Laura Mezquita, Spain		 Monday, 23 October 2023
Type: Poster Display
Abstract Number: 1509TiP
Lung Cancer The 1920-EORTC-BIORADON study: Molecular characterization of non-small cell lung cancer (NSCLC) and indoor radon exposure in Europe.
Laura Mezquita, Spain		 Monday, 23 October 2023
Type: Poster Display
Abstract Number: 1508TiP
Back to news list

Related News

  • EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

    11 Dec 2024

  • Minister F. Vandenbroucke visits EORTC Headquarters to strengthen collaborative efforts in clinical cancer research

    21 Nov 2024

  • IMMUcan has completed patient enrolment

    12 Nov 2024

  • EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients

    5 Nov 2024

  • Pink October at EORTC: Over 60 years of impactful breast cancer research

    29 Oct 2024

  • Spotlight on ENA 2024 News

    25 Oct 2024

  • Do regulations and policies undermine the social value of independent academic research?

    25 Oct 2024

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

    10 Oct 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

    8 Oct 2024

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival

    24 Sep 2024